RU2491953C2 - Соединения для лечения амилоидозов - Google Patents

Соединения для лечения амилоидозов Download PDF

Info

Publication number
RU2491953C2
RU2491953C2 RU2011100125/15A RU2011100125A RU2491953C2 RU 2491953 C2 RU2491953 C2 RU 2491953C2 RU 2011100125/15 A RU2011100125/15 A RU 2011100125/15A RU 2011100125 A RU2011100125 A RU 2011100125A RU 2491953 C2 RU2491953 C2 RU 2491953C2
Authority
RU
Russia
Prior art keywords
compound
amino acid
peptide
use according
disease
Prior art date
Application number
RU2011100125/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011100125A (ru
Inventor
Маркус МАНДЛЕР
Радмилла САНТИК
Харальд ВЕНИНГЕР
Эдит КОПИНИТС
Original Assignee
Аффирис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффирис Аг filed Critical Аффирис Аг
Publication of RU2011100125A publication Critical patent/RU2011100125A/ru
Application granted granted Critical
Publication of RU2491953C2 publication Critical patent/RU2491953C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2011100125/15A 2008-06-12 2009-06-12 Соединения для лечения амилоидозов RU2491953C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA952/2008 2008-06-12
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses

Publications (2)

Publication Number Publication Date
RU2011100125A RU2011100125A (ru) 2012-07-20
RU2491953C2 true RU2491953C2 (ru) 2013-09-10

Family

ID=41401983

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011100125/15A RU2491953C2 (ru) 2008-06-12 2009-06-12 Соединения для лечения амилоидозов

Country Status (14)

Country Link
US (1) US8409581B2 (enExample)
EP (1) EP2310033B1 (enExample)
JP (3) JP2011522840A (enExample)
KR (1) KR20110036039A (enExample)
CN (1) CN102123728B (enExample)
AT (2) AT506820B1 (enExample)
AU (1) AU2009257168B2 (enExample)
BR (1) BRPI0915136A2 (enExample)
CA (1) CA2723967A1 (enExample)
ES (1) ES2392789T3 (enExample)
IL (1) IL209894A (enExample)
MX (1) MX2010013657A (enExample)
RU (1) RU2491953C2 (enExample)
WO (1) WO2009149485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN103459421B (zh) 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
DK3137094T3 (da) 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
MX2021008035A (es) 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
CN115925987B (zh) * 2022-02-28 2026-05-05 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1172377A1 (en) * 1994-10-25 2002-01-16 The President And Fellows Of Harvard College Compounds and methods for inhibiting amyloid Beta-protein filament formation and neurotoxicity
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)
US20040265308A1 (en) * 1997-12-02 2004-12-30 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6861057B2 (en) * 1998-05-08 2005-03-01 Gemvax As Immunogenic β-amyloid peptide
EP1075270B1 (en) * 1998-04-06 2005-06-15 Advanced Immunit, Inc. Short peptide for treatment of neurological degenerative diseases
RU2004107695A (ru) * 1998-05-21 2005-08-27 Юниверситити Оф Теннесси Рисерч Фаундэушн (Us) Способы удаления амилоида с помощью анти-амилоидных антител

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CA2790433A1 (en) * 2004-10-25 2006-05-26 Northwestern University Anti-addl antibodies and uses thereof
WO2006136906A2 (en) * 2005-06-17 2006-12-28 Epfl Ecole Polytechnique Fédérale De Lausanne Switch-peptides as tool for the study of fibrillogenesis
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN101421299A (zh) * 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1172377A1 (en) * 1994-10-25 2002-01-16 The President And Fellows Of Harvard College Compounds and methods for inhibiting amyloid Beta-protein filament formation and neurotoxicity
US20040265308A1 (en) * 1997-12-02 2004-12-30 Neuralab Limited Prevention and treatment of amyloidogenic disease
EP1075270B1 (en) * 1998-04-06 2005-06-15 Advanced Immunit, Inc. Short peptide for treatment of neurological degenerative diseases
US6861057B2 (en) * 1998-05-08 2005-03-01 Gemvax As Immunogenic β-amyloid peptide
RU2004107695A (ru) * 1998-05-21 2005-08-27 Юниверситити Оф Теннесси Рисерч Фаундэушн (Us) Способы удаления амилоида с помощью анти-амилоидных антител
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)

Also Published As

Publication number Publication date
IL209894A0 (en) 2011-02-28
AT506820B1 (de) 2011-07-15
US20110171243A1 (en) 2011-07-14
AT509611A1 (de) 2011-10-15
ES2392789T3 (es) 2012-12-13
EP2310033B1 (en) 2012-09-05
JP2015110588A (ja) 2015-06-18
RU2011100125A (ru) 2012-07-20
AU2009257168B2 (en) 2015-01-22
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
AT506820A1 (de) 2009-12-15
AU2009257168A1 (en) 2009-12-17
AT509611B1 (de) 2012-04-15
JP5984867B2 (ja) 2016-09-06
BRPI0915136A2 (pt) 2019-09-24
WO2009149485A2 (en) 2009-12-17
JP5989074B2 (ja) 2016-09-07
IL209894A (en) 2015-08-31
CN102123728A (zh) 2011-07-13
MX2010013657A (es) 2011-04-11
EP2310033A2 (en) 2011-04-20
JP2011522840A (ja) 2011-08-04
JP2014139227A (ja) 2014-07-31
CN102123728B (zh) 2017-05-31
KR20110036039A (ko) 2011-04-06
CA2723967A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
RU2553345C2 (ru) Применение мимотопов для лечения бетта-амилоидозов
CN102123728B (zh) 用于治疗淀粉样变的化合物
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
US10517935B2 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
RU2532351C2 (ru) Применение мимеотопов альфа-синуклеиновых эпитопов для лечения заболеваний, связанных с тельцами леви
HK1152470B (en) Peptides for treating beta-amyloidoses

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160613